PEBBLE LABS

Dead / Cancelled — Cancelled — Section 8 (as of 13 Feb 2026)

What this means for you

This registration has been cancelled; it no longer blocks anyone on its own. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
88225549
Registration number
5819332
Mark type
Stylized text
Filed
11 Dec 2018
Published for opposition
14 May 2019
Registered
30 Jul 2019
Attorney of record
David S. Kerr

Goods and services

  • Class 042 — Scientific and technological services: Medical research and development in the field of synthetic biology, molecular biology, genetic engineering and bioinformatics; Design and development of biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals for use in pharmaceuticals, biotechnology, and medical and diagnostic applications; Research and development of biopharmaceutical compounds; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Research and development of biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit mosquito populations; Research and development biopharmaceutical compounds, namely, RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target genes; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit the expression of target pathogen genes in plants and animals; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit vector-borne diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit aquaculture-related diseases; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit mosquito populations; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce RNA-based therapeutic agents to inhibit bacterial quorum-sensing; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce eukaryotic-like mRNA; Research and development of genetically engineered organisms, namely, genetically engineered bacteria that produce that produce commercial compounds; Research and development of genetically engineered organisms, namely, genetically engineered algae that produce that produce waxes; Research and development of pharmaceuticals, therapeutics, and biologics; Research and development of new biological products for therapeutic use

Owner

Prosecution history

  • 13 Feb 2026 — CANCELLED SEC. 8 (6-YR)
  • 30 Jul 2024 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
  • 06 Jan 2021 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
  • 09 Oct 2019 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
  • 30 Jul 2019 — REGISTERED-PRINCIPAL REGISTER
  • 14 May 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 14 May 2019 — PUBLISHED FOR OPPOSITION
  • 24 Apr 2019 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 10 Apr 2019 — LAW OFFICE PUBLICATION REVIEW COMPLETED
  • 05 Apr 2019 — ASSIGNED TO LIE
  • 14 Mar 2019 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 14 Mar 2019 — EXAMINER'S AMENDMENT ENTERED
  • 14 Mar 2019 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
  • 14 Mar 2019 — EXAMINERS AMENDMENT E-MAILED
  • 14 Mar 2019 — EXAMINERS AMENDMENT -WRITTEN

View this trademark record on Marksy